unknown
Stage
2011
Founded
1
Investors
About
Algiax is a clinical-stage biotech company developing AP-325 to treat peripheral post-surgical neuropathic pain; its Phase 2 study reported meaningful pain reduction with fewer side effects. The company focuses on developing novel therapeutics for neuropathic pain.
Explore Algiax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.